PureTech Health plc Stock price

Equities

PRTC

GB00BY2Z0H74

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:18 2024-02-27 am EST 5-day change 1st Jan Change
210.5 GBX -0.24% Intraday chart for PureTech Health plc +13.54% +8.39%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2023 * 9.47M Sales 2024 * 45.33M Capitalization 721M
Net income 2023 * -134M Net income 2024 * -128M EV / Sales 2023 * 46.3 x
Net cash position 2023 * 283M Net cash position 2024 * 355M EV / Sales 2024 * 8.07 x
P/E ratio 2023 *
-5.16 x
P/E ratio 2024 *
-5.13 x
Employees 111
Yield 2023 *
-
Yield 2024 *
-
Free-Float 85.71%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.24%
1 week+13.54%
Current month+6.64%
1 month+5.78%
3 months+31.56%
6 months+13.42%
Current year+8.39%
More quotes
1 week
186.00
Extreme 186
218.00
1 month
179.20
Extreme 179.2
218.00
Current year
179.20
Extreme 179.2
218.00
1 year
139.00
Extreme 139
242.93
3 years
139.00
Extreme 139
446.00
5 years
139.00
Extreme 139
447.66
10 years
110.00
Extreme 110
447.66
More quotes
Managers TitleAgeSince
Founder 54 15-05-07
Director of Finance/CFO 59 17-03-01
Chief Tech/Sci/R&D Officer 57 21-08-12
Members of the board TitleAgeSince
Chairman 81 13-12-31
Director of Finance/CFO 59 17-03-01
Founder 75 15-05-07
More insiders
Date Price Change Volume
24-02-27 210.5 -0.24% 358,218
24-02-26 211 -1.17% 537,094
24-02-23 213.5 +11.55% 1,723,416
24-02-22 191.4 +2.35% 260,191
24-02-21 187 +0.86% 190,434

Delayed Quote London S.E., February 27, 2024 at 11:35 am EST

More quotes
PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.671 USD
Average target price
5.906 USD
Spread / Average Target
+121.13%
Consensus
  1. Stock
  2. Equities
  3. Stock PureTech Health plc - London S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW